Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Non-Malignant Blood DisordersLymphomaMultiple Myeloma (MM)

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Lancet Haematol

Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S, Nine-I investigators.

doi: 10.1016/S2352-3026(21)00060-0

Lymphoma

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

J Am Coll Cardiol

Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, Steingart RM, Mahmood SS, Schaffer WL, Perales MA, Shouval R

doi: 10.1016/j.jacc.2021.08.044

Gastrointestinal CancerSkin Cancer

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

Cancer Treat Rev.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C

doi: 10.1016/j.ctrv.2017.06.002.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

doi: 10.1007/s00432-018-2805-3.

Further Publications

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Eur J Cancer.

Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J

doi: 10.1016/j.ejca.2020.03.017.

Further Publications

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

JAMA Oncol.

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J

doi: 10.1001/jamaoncol.2020.0726.

Lung, Respiratory and Thoracic CancerSkin Cancer

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1

Eur J Cancer.

Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S

doi: 10.1016/j.ejca.2018.03.006.

Lymphoma

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

N Engl J Med.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH

doi: 10.1056/NEJMoa1708566.

Leukemia

Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy

Blood

Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J

doi: 10.1182/blood.2020009515

Related content